BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Coagulation
,
Allergy to pollen
,
Heart
,
Alcohol
,
Fenofibrate
,
rs2476601
,
SLC12A1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
sn 38
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Colon cancer HT 115 cells expressing UGT1A isoform 2 shRNA and treated with SN-38
Colorectal cancer drug-sensitive parental cell lines and chemotherapy-resistant sub cell lines
Explore Curated Studies Results
Literature
Most Relevant Literature
UGT1A1 genotype-guided dosing of irinotecan: time to prioritize patient safety.
Synergistic cytotoxicity of irinotecan combined with polysaccharide-based nanoparticles for colorect…
Development and Evaluation of Biotin Functionalized Fullerenes for the Delivery of Irinotecan to Col…
Recent advances in SN-38 drug delivery system.
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in P…
EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors
UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ